Ottawa Hospital Research Institute, Ottawa, ON, Canada.
University of Ottawa, Ottawa, ON, Canada.
Med Decis Making. 2019 Oct;39(7):805-815. doi: 10.1177/0272989X19868193. Epub 2019 Aug 17.
Patient decision aids (PtDAs) are effective interventions to support patient involvement in health care decisions, but there is little use in practice. Our study aimed to determine subsequent PtDA use in clinical practice following published randomized controlled trials. A descriptive study using an e-mail-embedded questionnaire survey targeting authors of 133 trials included in Cochrane Reviews of PtDAs (106 authors). We classified PtDA level of use as a) implementation, defined as integrating within care processes; b) dissemination to target users with planned strategies; and c) diffusion, defined as passive, unplanned spread. We conducted content analysis to identify barriers and enablers guided by the Ottawa Model of Research Use. Ninety-eight authors responded (92.5%) on 108 trialed PtDAs. Reported levels of use were implementation ( = 29; 28%), dissemination to target user(s) ( = 9; 9%), and diffusion ( = 7; 7%); 57 (55%) reported no uptake, and 1 had no response (1%). Barriers to use in clinical practice were identified at the level of researchers (e.g., lack of posttrial plan), PtDAs (e.g., outdated, delivery mechanism), clinicians (e.g., disagreed with PtDA use), and practice environment (e.g., infrastructure support; funding). Enablers were online delivery, organizational endorsement (e.g., professional organization, charity, government), and design for and integration into the care process. Self-report bias and potential for recall bias. Only 44% of PtDA trial authors indicated some level of subsequent use following their trial. The most commonly reported barriers were lack of funding, outdated PtDAs, and clinician disagreement with PtDA use. To improve subsequent use, researchers should codesign PtDAs with end users to ensure fit with clinical practice and develop an implementation plan. National systems (e.g., platforms, endorsement, funding) can enable use.
患者决策辅助工具(PtDAs)是支持患者参与医疗保健决策的有效干预措施,但在实践中应用很少。我们的研究旨在确定在发表的随机对照试验后,临床实践中随后使用 PtDAs 的情况。这是一项描述性研究,使用电子邮件嵌入问卷调查了 Cochrane 患者决策辅助工具评价中 133 项试验的作者(106 名作者)。我们将 PtDA 的使用水平分为 a)实施,定义为整合到护理流程中;b)向目标用户传播,使用计划策略;c)扩散,定义为被动、无计划的传播。我们进行了内容分析,根据渥太华研究使用模型确定了障碍和促进因素。在 108 项试验的 PtDAs 中,98 名作者(92.5%)回复了报告。使用水平报告为实施(=29;28%)、向目标用户传播(=9;9%)和扩散(=7;7%);57 项(55%)报告没有采用,1 项没有回复(1%)。在临床实践中使用的障碍在研究人员(例如,缺乏试验后计划)、PtDAs(例如,过时、传递机制)、临床医生(例如,不同意使用 PtDA)和实践环境(例如,基础设施支持;资金)层面被确定。促进因素是在线交付、组织认可(例如,专业组织、慈善机构、政府)以及针对和整合到护理流程的设计。自我报告偏差和潜在的回忆偏差。只有 44%的 PtDA 试验作者在试验后表示进行了某种程度的后续使用。报告最多的障碍是缺乏资金、PtDAs 过时和临床医生不同意使用 PtDA。为了提高后续使用,研究人员应与最终用户共同设计 PtDAs,以确保其与临床实践相匹配,并制定实施计划。国家系统(例如,平台、认可、资金)可以实现使用。